Corcept Therapeutics (CORT) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Corcept Therapeutics (NASDAQ:CORT) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02), Yahoo Finance reports. The company had revenue of $53.30 million during the quarter, compared to the consensus estimate of $53.30 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The company’s revenue was up 123.9% on a year-over-year basis. During the same quarter last year, the business earned $0.04 earnings per share.

Shares of Corcept Therapeutics (NASDAQ CORT) opened at $16.09 on Friday. Corcept Therapeutics has a one year low of $8.50 and a one year high of $25.96. The company has a market cap of $1,799.74, a P/E ratio of 55.48 and a beta of 1.68.

Several research firms have recently issued reports on CORT. BidaskClub cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 7th. Stifel Nicolaus decreased their price objective on shares of Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Monday, February 5th. Piper Jaffray Companies set a $30.00 price objective on shares of Corcept Therapeutics and gave the company a “buy” rating in a report on Monday, February 5th. Finally, Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $21.00.

In related news, insider Robert S. Fishman sold 8,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $16.60, for a total transaction of $132,800.00. Following the completion of the sale, the insider now directly owns 8,000 shares of the company’s stock, valued at $132,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 24,000 shares of company stock valued at $415,920. Company insiders own 19.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Earnings History for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit